-
-
-
-
-
-
-
Sanofi reports positive phase 2 trial results for AATD treatment
-
-
-
-
-
-
-
Press Release: Q1 2026: double-digit sales and business EPS growth
-
-
-
-
-
-
-
Sanofi cut to "neutral" at BofA on CEO change, shares drop over 6%
-
-
-
-
-
-
-
Sanofi earnings preview: Stable quarter expected
-
-
-
-
-
-
-
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
-
-
-
-
-
-
-
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
-
-
-
-
-
-
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
1,227,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

